16 Apr 2009 07:00
| Press Release | 16 April 2009 |
LiDCO Group Plc
("LiDCO" or "the Company")
LiDCO extends collaboration with BD
LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, today has extended its exclusive collaboration with BD (Becton, Dickinson and Company), a leading global medical technology company dedicated to helping all people live healthy lives (see www.bd.com).
In June 2007, LiDCO signed an exclusive UK marketing collaboration with Becton, Dickinson U.K. Limited. LiDCO today announces the expansion of this exclusive collaboration with BD. Under the amended and restated terms of the agreement, LiDCO and BD will extend their exclusive marketing collaboration to include additional territories. The collaboration provides that BD Medical - Medical Surgical Systems regional sales teams will provide sales and marketing support for LiDCO products in territories additional to the UK. This marketing collaboration will result in an enhanced product offering for BD's customers as well as superior sales coverage for both LiDCO and LiDCO's network of distributors.
In a separate agreement, LiDCO have entered an exclusive distribution and sales relationship for the LiDCOrapid Monitor with BD in Japan. This relationship will result in an enhanced product offering for BD customers, as well as improved access to LiDCO's technology by Japanese clinicians and patients.
Dr Terry O'Brien, Chief Executive of LiDCO, commenting on the agreements stated: "This licensing arrangement in Japan and expansion of our marketing collaboration with a major corporation of the stature of BD further enhances our capabilities to provide our acute care customers with the best possible products and services to improve outcomes and reduce complications such as infections. We are very pleased to share a commitment with BD towards expanding access to innovative technologies that improve outcomes in the critically ill."
Hideyuki Ashikaga, President, BD in Japan stated:
"BD designs and markets innovative products that address significant healthcare problems and deliver demonstrably higher benefits to patients, healthcare workers and researchers. Collaborating with LiDCO, an innovative company in an important healthcare market, will reinforce our capabilities to serve that market, in line with our corporate purpose of 'Helping all people live healthy lives'".
- ENDS -
For more information please contact:
| LiDCO Group Plc | |
| Terry O'Brien - Chief Executive John Rowland - Company Secretary | Tel: +44 (0)20 7749 1500 www.lidco.com |
| FinnCap | |
| Geoff Nash/ Stephen Norcross/ Marc Young | +44 (0)20 7600 1658 www.finncap.com |
Media enquiries
| Abchurch Communications | |
| Heather Salmond / Stephanie Cuthbert / Simone Alves | +44 (0)20 7398 7728 www.abchurch-group.com |
About LiDCO Group Plc
LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.
The Company's manufacturing facility is in Hoxton, London, and its current products are:
* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)
* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery.
| Early and rapid warning of change | |
| Clear indication of therapeutic route: fluid or drug | |
| Quantification of hemodynamic response, particularly stroke volume | |
| Permits more effective delivery of fluids - the right amount at the right time | |
| Advanced hemodynamic care has been shown to: - Contribute to reduced morbidity and complications - Reduce length of stay - Reduce overall cost of care |
* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid Monitors.
* LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase
LiDCO Distribution Network:
The Company sells direct to hospitals in the UK, and elsewhere predominantly through a worldwide network of specialty critical care and anesthesia distributors.